Analyst Upgrades

• Akamai (AKAM) to overweight from neutral at Piper Jaffray.
• Las Vegas Sands (LVS) to buy from neutral at UBS.
• Aetna (AET) to Outperform from market perform at Leerink.
• Hot Topic (HOTT) to buy from neutral at Janney Capital.
• Colonial Properties (CLP) upgraded to Outperform from market perform at FBR Capital and to buy from hold at Citigroup.
• Altera (ALTR) to buy from hold at Citigroup.
• American Reprographics (ARC), CarMax (KMX) and American Campus (ACC) to outperform from neutral at RW Baird.
• Zebra Tech (ZBRA) to neutral from underweight at JPMorgan.
• IMAX (IMAX) to buy from hold at Canaccord.
• Basic Energy (BAS) to neutral from sell at Goldman.
• Mednax (MD) to buy from neutral at BofA/Merrill.
• UTi Worldwide (UTIW) to buy from hold at Stifel Nicolaus.

Analyst Upgrades

• Aetna (AET) to buy from neutral at Goldman.
• Kellogg (K) to buy from neutral at UBS.
• PetSmart (PETM) to outperform from market perform at JMP Securities.
• NetApp (NTAP) and Scripps Networks (SNI) to buy from hold at Wunderlich.
• Thoratec (THOR) to buy from hold at Auriga.
• ArcelorMittal (MT) to overweight from neutral at HSBC.
• Bristol-Myers (BMY) to outperform from neutral at Cowen.
• Eaton Vance (EV) to neutral from sell at Ticonderoga.
• Adtran (ADTN) to buy from underperform at BofA/Merrill.

Friday's fourth-quarter GDP numbers offered more evidence that the economy is picking up steam, but one of the biggest obstacles to the recovery remains the stubbornly high unemployment rate. We'll find out whether there's been any movement on that front when employment data for January comes out this week. The Challenger Job-Cut report and ADP employment data are due Wednesday, and the government's unemployment rate on Friday. Another mild increase in jobs is expected, in line with the three-month average, but not enough to significantly reduce the unemployment rate.

Also look for the ISM manufacturing and nonmanufacturing indexes this week, as well as the Chicago PMI and the New York NAPM index. And Fed Chairman Ben Bernanke will speak to the National Press Club on Thursday.

Over the next couple decades, the healthcare industry will undergo major disruptive changes. Part of this will be the result of Obama care. And of course, a key factor will be the onslaught of the Baby Boomers, as they reach the retirement zone.

To deal with the costs and the complexities, the federal government is pushing hard for medical records. It seems like no-brainer, right?

Well, the major health insurers are certainly waking up. For example, this week Aetna (AET) agreed to shell out a cool $500 million for Medicity.

It will be a busy week. Republicans are poised to gain control of the House of Representatives and gain governorships in Tuesday's mid-term elections. Also, the Federal Reserve is expected to announce another round of quantitative easing Wednesday, following the FOMC meeting. Major retailers are scheduled to report October same-store sales Thursday, while the October unemployment rate, announced on Friday, is expected to remain at 9.6%.

Toyota's (TM) fiscal second-quarter results will be one of the highlights on the earnings front this week. After three periods of way underestimating Toyota's earnings, have the analysts surveyed by Thomson Reuters got it right this time? The stock sure could use a boost. Teva Pharmaceuticals (TEVA) is in a similar situation; i.e., high expectations for this week's quarterly results but a stock in need of a boost. Marathon (MRO) and Starbucks (SBUX) are also expected to post strong earnings growth this week, but both stocks are riding high.

Analyst Upgrades

• Deutsche Bank upgraded Illinois Tool Works (ITW) to buy from hold, citing valuation and the company's strong revenue performance. The firm has a $60 price target for shares.
• Goldman upgraded PPD Inc. (PPDI) to buy from hold and raised its price target to $31 from $28. The firm expects strong top line growth and bookings momentum for the upgrade.
• Stifel Nicolaus upgraded Insituform Technologies (INSU) to buy from hold based on higher estimates for sewer rehab and energy. The firm has a $31 target on the stock.
• Patterson-UTI Energy (PTEN) was upgraded to overweight from equal weight at Morgan Stanley.
• Wisconsin Energy (WEC) and Northeast Utilities (NU) were upgraded to buy from neutral at UBS.
• Rockwell Collins (COL) was upgraded to buy from neutral at BofA/Merrill.

Humana Inc. (HUM), whose colleagues include Aetna Inc. (AET) and CIGNA Corporation (CI), reported Q1 earnings earlier today. The health insurer isn't doing so well, unfortunately. In late trading, shares were down almost 3% to $43.73. Volume is above the norm, as you might expect.

I've covered many stocks that are near their 52-week highs, but this one doesn't fall into such a desirable category. Alas, the 52-week high on the shares stands at $52.66. And, as you can see from the following one-year chart, the stock began its pullback after it topped out in January. Since then, things haven't been too exciting.

Analyst Upgrades

• UBS upgraded Yum! Brands (YUM) to buy from neutral, citing valuation, improving momentum and stabilizing China fast-food sales. The firm raised its target to $44 from $38.
• United Technologies (UTX) was upgraded to outperform from neutral at Cowen.
• Needham upgraded Arris (ARRS) to buy from hold, citing valuation and positive near-term business trends. The firm has a $16 price target on shares.
• Warnaco (WRC) was upgraded to outperform from neutral at Credit Suisse.
• Aetna (AET) was upgraded to neutral from underperform at BofA/Merrill.
• Nestle (NSRGY) was upgraded to overweight from neutral at JPMorgan.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Aetna Inc. (AET) shares declined after the insurer issued a surprise earnings warning for 2010.
• Alcoa Inc. (AA) swung to a smaller-than-expected Q4 profit even as revenue declined, sending shares lower.
• Carter's Inc. (CRI) posted strong Q3 earnings that topped estimates and same-store sales growth.
• Chevron Corp. (CVX) shares declined slightly after the company issued a surprise earnings warning.
• Con-Way Inc. (CNW) was downgraded due in part to concerns about near-term earnings.

Analyst Upgrades

• Credit Suisse views Bank of America (BAC) as the "cheapest" large-cap bank and said the recent TARP repayment removes a significant overhang. The firm upgraded shares to outperform from neutral and raised its target to $21 from $17.
• Piper Jaffray upgraded Bed Bath & Beyond (BBBY) to neutral from underweight following the company's better-than-expected Q3 results. The firm has a $43 price target on the stock.
• Caris upgraded Zumiez (ZUMZ) to above average from average following the company's better-than-expected December sales report. The firm raised its target on shares to $17 from $14.
• Humana (HUM) was upgraded to equal weight from underweight at Barclays.
• Zimmer (ZMH) was upgraded to buy from neutral at BofA/Merrill.
• Applied Industrial (AIT) was upgraded to buy from hold at KeyBanc.

Here are some highlights from last week's earnings coverage from BloggingStocks:

• Aetna Inc. (NYSE: AET) reported better-than-expected Q3 earnings and revenue, sending shares higher.
• Allergan Inc. (NYSE: AGN) reported better-than-expected Q3 numbers, sending shares higher.
• Bare Escentuals Inc. (NASDAQ: BARE) Q3 profit easily topped analysts' estimates, and shares surged.
• Cabot Oil & Gas Corp. (NYSE: COG) received an upgrade following the release of its Q3 numbers.
• Estee Lauder Companies Inc. (NYSE: EL) reported strong Q1 results, sending shares higher.
• E*Trade Financial Corp. (NASDAQ: ETFC) reported a smaller-than-expected net loss for Q3.
• Goodyear Tire & Rubber Co. (NYSE: GT) Q3 earnings topped estimates and revenue was up sequentially.

Even as the battle over health care reform rages on Capitol Hill, we are seeing a flurry of third quarter reports from insurers.

Aetna Inc. (NYSE: AET) reported Thursday that its third-quarter profit rose 18% from a year ago to $308.2 million, or $0.69 per share, topping Wall Street's expectations. Revenue came in at $8.72 billion, versus the consensus of $8.68 billion. Aetna also said share repurchases totaled 3.9 million at a cost of $114 million in the third quarter of 2009.